Company Overview

Anogen-Yes Biotech Laboratories Ltd. (since 1989)

Anogen is the trade name of Yes Biotech Laboratories Ltd., a Canadian biopharmaceutical company located in Toronto, Ontario, Canada. Our company has been producing antibody products for research, diagnostic and therapeutic applications for more than thirty years. Our broad technology platform enables us to design and develop a variety of products including monoclonal and polyclonal antibodies, immunoassay kits, matched antibody pairs, immunoglobulin, bioactive peptides, recombinant proteins and humanized monoclonal antibodies with high producers. We distribute our products worldwide. Our name is a recognized quality supplier to research organizations and large antibody suppliers. We are committed to developing and commercializing antibody-related therapeutics and diagnostics to combat various diseases including inflammatory and autoimmune disorders, cardiovascular diseases and cancer. To ensure that our customers are provided with the highest level of quality products and services, Anogen is ISO 13485 certified since 2000.

A milestone of Life Science in the 20th century is the mapping of human genome by genomics and transcriptomics technologies. So far, approximately 20,000 to 30,000 genes have been mapped out on human genome. Many genes encode multiple proteins. There are estimated more than two million human proteins accomplishing a human life. Understanding the function and structure of these proteins is important for the wellbeing of mankind. Proteomics has become the new endeavour of life science research. To carry out the broad-scale experiments on these proteins, millions of specific antibodies (or other binding ligands) are needed. Furthermore, antibodies have become a novel resource for pharmaceutical study and dozens of them have been successfully utilized in of therapeutic applications. The gap between antibody supply and demand has been huge. Developing new antibodies will not only fulfil the request from life science research, but also provide a valuable reservoir for diagnostics and therapeutics development. We believe that antibodies are a group of the most promising biological products in the 21st century.

 

 

Founder's Profile:

Dr. George Ye is the Chief Scientific Officer and President of Anogen-Yes Biotech Laboratories Ltd since 1989. Dr. Ye is a leading scientist in the field of monoclonal antibody applications and is one of the world's pioneers in anti-chemokine therapy for refractory and complicated diseases.

During the SARS epidemic in 2003, Dr. Ye went to Foshan, Guangdong, China to research the SARS virus. As a result of his research, Dr. Ye discovered and introduced to the world the novel "anti-cytokine storm" bio-defense strategy. In his more than 20 years of research on Alzheimer's disease (AD), Dr. Ye concluded that, given the difficulties of effectively treating patients who have already been affected by AD, a paradigm shift was needed in the fight against AD. To address this need, Dr. Ye introduced to the global community the concept of Pre-AD treatment to prevent the onset of AD. He achieved remarkable results using anti-Abeta42, anti-Tau and other anti-inflammatory antibodies to prevent the onset of AD in mice.

 

 

 

Contact Us